• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Deloitte accuses Zimmer Biomet of filing ‘through the looking glass’ suit

Deloitte accuses Zimmer Biomet of filing ‘through the looking glass’ suit

November 10, 2025 By Chris Newmarker

This is the logo of Zimmer Biomet.Deloitte wants a New York judge to dismiss a lawsuit in which Zimmer Biomet seeks more than $172 million in damages for what it called a disaster of an enterprise resource planning software project.

The British accounting and consulting firm filed a motion to dismiss on Nov. 7 in the Supreme Court of the State of New York in Manhattan. ZB filed the suit in September.

An accompanying memorandum of law evoked some 19th-century British children’s literature:

“Zimmer’s complaint reads like a ‘through the looking glass’ version of its relationship with Deloitte. Far from shirking its obligations as Zimmer alleges, Deloitte served Zimmer diligently and ably throughout its engagement. Through Deloitte’s skill and hard work, Zimmer managed to replace its outdated and inefficient software systems with a new, state-of-the-art system that has yielded significant, tangible benefits to Zimmer’s operations and bottom line. Outside of the complaint and prior to its filing, Zimmer itself acknowledged the value of Deloitte’s services on multiple occasions. For years, Zimmer not only described the project as a ‘success,’ it also expressly approved Deloitte’s deliverables and repeatedly praised Deloitte’s work in effusive terms. The few issues Zimmer — and its lawyers — now depict as catastrophic, Zimmer previously described as ‘short term’ and ‘contained.’ Now that it must pay for Deloitte’s valuable services, however, Zimmer has changed its tune. It decries and demeans Deloitte’s work — even brazenly alleging fraud — in an effort to avoid its obligations. Zimmer even seeks to blame Deloitte for problems that Zimmer itself caused and Deloitte then fixed. Zimmer’s allegations have no factual merit, as discovery would demonstrate. But this case should end now because, for many reasons, Zimmer’s complaint fails under the law.”

Deloitte claims Zimmer Biomet failed to properly notify it of a breach of contract under the terms of their agreement.

ZB’s lawsuit, according to Deloitte, falls short on its fraud claims and doesn’t demonstrate a special relationship between the two companies that included fiduciary responsibility. According to Deloitte and its lawyers, ZB’s claim under the New York General Business Law fails because a private contract between two parties is not “consumer-oriented” conduct.

ZB cited the mounting challenges from what it described as a botched ERP system implementation when it released Q3 earnings and reduced its full-year 2024 guidance  in October 2024. ZB said in its lawsuit that the device manufacturer was barely operational through the third quarter of 2024, unable to ship or receive products, issue invoices, or generate basic sales reporting.

Filed Sept. 4, Zimmer Biomet’s complaint accuses the Deloitte team of being incompetent and unqualified. The new ERP was supposed to save hundreds of millions of dollars for Zimmer Biomet’s operations in North America and Latin America, but ZB says it was instead a severely flawed system limited to North America.

ZB is claiming at least $173 million in damages, including the $94 million in fees paid to Deloitte, an additional $15 million invoiced as Deloitte unsuccessfully sought to fix its own mistakes, and ZB’s own $72 million in additional post-go-live costs.

Only through an extraordinary internal effort was Zimmer Biomet able to prevent even more extensive damage to its business and customer relationships,” Zimmer Biomet said in its complaint. “… Deloitte’s implementation of S/4 for Zimmer Biomet was a disaster.”

Filed Under: Business/Financial News, Featured, In-Depth Coverage, Legal News, Orthopedics, Special Content Tagged With: Deloitte, Zimmer Biomet

More recent news

  • Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
  • Autonomix taps former Medtronic FDA counsel head for board of directors
  • Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
  • Science Corp. names president as it looks to roll out vision-restoring implant
  • Mindray looks to fill hospital ventilator gap left by Philips’ exit

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy